You've been to three doctors. Your fatigue won't lift, your brain fog makes it hard to finish sentences, and your sleep is fractured. Every lab comes back normal. You're told it's stress, or age, or perhaps anxiety. But you know something is off.
This is the diagnostic gap we address with root-cause medicine—a structured, evidence-based framework that investigates beyond routine screening panels. Standard labs are designed to catch overt disease. We use an expanded biomarker strategy to identify subclinical dysfunction before it progresses.
Why do standard lab ranges miss early dysfunction?
Conventional reference ranges are population-based: they capture the middle 95% of tested individuals, many of whom are metabolically compromised. A fasting glucose of 99 mg/dL is technically normal (under 100 mg/dL), but it signals pre-diabetes when optimal function sits below 90 mg/dL. Similarly, TSH can register at 3.5 mIU/L—within the standard 0.5–5.0 range—while a patient experiences hypothyroid symptoms that resolve once TSH is optimized below 2.5 mIU/L, as suggested by research linking subclinical hypothyroidism to symptom burden.
Functional reference ranges, derived from cohorts without chronic disease, define narrower thresholds for optimal physiology. The Institute for Functional Medicine publishes frameworks that integrate this approach: instead of asking "Is this value abnormal enough for diagnosis?", we ask "Is this value supporting or undermining cellular function?"
The five-pillar root-cause workup we use in our clinic
Our investigation follows a structured model adapted from functional medicine's core systems. Each pillar corresponds to a biological network; dysfunction in one often cascades into others.
1. Metabolic & energy regulation
We measure fasting insulin alongside glucose. Insulin resistance develops years before glucose rises. A fasting insulin above 5 μIU/mL, even with normal glucose, indicates early metabolic strain. Studies show that hyperinsulinemia predicts cardiovascular events independent of glucose levels. We also run hemoglobin A1c and, where warranted, continuous glucose monitoring to observe postprandial glycemic variability—patterns that standard screening misses.
For mitochondrial function, we assess lactate, CoQ10 status, and sometimes organic acids (via urine) to identify energy-production bottlenecks. Chronic fatigue often traces to impaired ATP synthesis, not adrenal exhaustion.
2. Thyroid & hormone axis
A standard thyroid panel—TSH alone—catches overt disease but ignores peripheral conversion issues. We order TSH, free T3, free T4, reverse T3, and thyroid antibodies (anti-TPO, anti-thyroglobulin) as baseline. Low T3 with normal TSH suggests poor T4-to-T3 conversion, common in chronic inflammation or nutrient deficiency (selenium, zinc). Elevated reverse T3 can signal metabolic stress or non-thyroidal illness syndrome.
Sex hormones also drive symptom burden. We measure estradiol, progesterone, testosterone (total and free), DHEA-S, and SHBG in both men and women. Hormonal imbalance—whether estrogen dominance, low androgens, or disrupted cortisol rhythm—manifests as fatigue, mood instability, and cognitive fog. Data from the NHANES cohort link low testosterone in men to increased all-cause mortality, yet it's rarely screened outside urology.
3. Inflammatory & immune markers
Chronic low-grade inflammation—termed metaflammation—underpins most age-related disease. Standard CRP is too coarse; we use high-sensitivity CRP (hs-CRP), targeting values below 1.0 mg/L for cardiovascular protection (AHA/CDC statement). We also measure homocysteine (elevated in B-vitamin deficiency and associated with vascular damage), fibrinogen, and sometimes IL-6 or TNF-alpha when autoimmunity is suspected.
Food sensitivities can perpetuate inflammation. While IgE testing identifies true allergies, IgG food panels remain controversial; we order them selectively and interpret cautiously, focusing on elimination-rechallenge protocols rather than panel results alone.
4. Micronutrient status & oxidative stress
Vitamin D deficiency is near-ubiquitous in indoor populations; we target 50–70 ng/mL for immune and bone health, higher than the 20 ng/mL threshold used to diagnose deficiency. Magnesium (measured via RBC magnesium, not serum), B vitamins (methylmalonic acid for B12 function, not just serum B12), zinc, selenium, and omega-3 index (HS-Omega-3 Index by OmegaQuant) complete the core micronutrient panel.
Oxidative stress markers—including 8-OHdG (urine) or plasma malondialdehyde—help quantify cellular damage in patients with chronic fatigue or suspected mitochondrial dysfunction, though these remain research-adjacent rather than routine.
5. Gut integrity & microbiome
The gut-systemic axis is central to inflammation, neurotransmitter production, and immune regulation. We don't order stool testing reflexively, but when symptoms suggest gut involvement—bloating, irregular bowel habits, food reactivity—we use validated assays like the GI-MAP by Diagnostic Solutions (qPCR-based, FDA-registered) or Genova Diagnostics' GI Effects panel. These assess pathogen load, commensal diversity, inflammatory markers (calprotectin, secretory IgA), and markers of permeability (zonulin).
Small intestinal bacterial overgrowth (SIBO) is diagnosed via lactulose or glucose breath testing when bloating and malabsorption dominate. Meta-analyses show SIBO prevalence of 30–80% in IBS populations, yet it remains under-tested in primary care.
How we synthesize findings into a treatment plan
Once data is gathered, we map patterns across systems. A patient with elevated fasting insulin, low free T3, suboptimal vitamin D, and elevated hs-CRP doesn't have four separate problems—they have a unified metabolic and inflammatory state that requires coordinated intervention: dietary modification (often time-restricted eating or carbohydrate titration), targeted supplementation (omega-3, magnesium, activated B vitamins), thyroid support if indicated, and stress modulation (HRV biofeedback, sleep optimization).
We retest every 8–12 weeks. Functional markers shift faster than structural disease, so trends matter. Improvement in fasting insulin or hs-CRP within three months confirms we're moving in the right direction—and gives patients tangible feedback that their efforts are working.
The evidence base for this approach
Functional medicine is not alternative medicine. The Cleveland Clinic Center for Functional Medicine published a 2019 cohort study showing significant improvements in quality-of-life scores, inflammatory markers, and medication burden in patients treated with functional medicine protocols compared to usual care. The interventions—nutrition, stress reduction, sleep hygiene, targeted nutraceuticals—are supported by mechanistic research in immunology, endocrinology, and gastroenterology.
Critics rightly caution against overtesting and unfounded supplement protocols. We agree. Every test we order changes management. Every intervention has a biological rationale and an exit strategy. We are physicians first—trained to integrate evidence, not abandon it.
When to consider a root-cause investigation
This approach is appropriate when:
- Standard labs are normal but symptoms persist for more than three months
- You have multiple vague complaints (fatigue, brain fog, sleep disturbance, GI upset) without a unifying diagnosis
- You've been told "it's just stress" or "it's normal aging" but you're not convinced
- You have a chronic condition (autoimmunity, metabolic syndrome) and want to address upstream drivers, not just suppress symptoms
- You're optimizing for longevity and cognitive performance, not just disease absence
In our clinic, the root-cause workup typically spans two visits: an initial 60-minute consultation to build a timeline and systems review, followed by lab interpretation and treatment planning two weeks later. We schedule follow-ups quarterly in the first year, then transition to annual optimization visits once biomarkers stabilize.
